RT Journal Article
SR Electronic
T1 Estimating the impact of COVID-19 vaccine allocation inequities: a modeling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.18.22282514
DO 10.1101/2022.11.18.22282514
A1 Gozzi, Nicolò
A1 Chinazzi, Matteo
A1 Dean, Natalie E.
A1 Longini, Ira M.
A1 Halloran, M. Elizabeth
A1 Perra, Nicola
A1 Vespignani, Alessandro
YR 2022
UL http://medrxiv.org/content/early/2022/11/18/2022.11.18.22282514.abstract
AB Access to COVID-19 vaccines on the global scale has been drastically impacted by structural socio-economic inequities. Here, we develop a data-driven, age-stratified epidemic model to evaluate the effects of COVID-19 vaccine inequities in twenty lower middle and low income countries (LMIC) sampled from all WHO regions. We focus on the first critical months of vaccine distribution and administration, exploring counterfactual scenarios where we assume the same per capita daily vaccination rate reported in selected high income countries. We estimate that, in this high vaccine availability scenario, more than 50% of deaths (min-max range: [56% − 99%]) that occurred in the analyzed countries could have been averted. We further consider a scenario where LMIC had similarly early access to vaccine doses as high income countries; even without increasing the number of doses, we estimate an important fraction of deaths (min-max range: [7% − 73%]) could have been averted. In the absence of equitable allocation, the model suggests that considerable additional non-pharmaceutical interventions would have been required to offset the lack of vaccines (min-max range: [15% − 75%]). Overall, our results quantify the negative impacts of vaccines inequities and call for amplified global efforts to provide better access to vaccine programs in low and lower middle income countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMC and AV were partially supported by the Bill & Melinda Gates Foundation (award number INV006010). ND, MEH and IML acknowledge support from NIH-R01 AI139761. MEH, IML, and AV acknowledge support from the Ron Conway Family and the Emerson Collective. We acknowledge support from Google Cloud and Google Cloud Research Credits program. The content is solely the responsibility of the authors. All authors thank the High Performance Computing facilities at Greenwich University. N.G. acknowledges support from the DTA3/COFUND project funded by the European Union's Horizon 2020 research innovation programme under the Marie Skłodowska Curie Actions grant agreement No 801604.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors